Repeated citalopram treatment but not stress exposure attenuates hypothalamic-pituitary-adrenocortical axis response to acute citalopram injection.
Many experimental, clinical and epidemiological studies have shown a direct connection between exposure to stress or adverse life events and disease, but little is known about the effect of stress on the action of drugs. The aim of this study was to test the hypothesis that previous exposure to stress changes the action of the antidepressant drug citalopram (10 mg/kg, i.p.) on hypothalamic-pituitary-adrenocortical (HPA) axis function, gene expression of selected neuropeptides and serotonin reuptake. Three different stress models were used, which included immobilization, restraint and unpredictable stress stimuli. Samples of plasma for hormone measurement were taken from conscious cannulated animals. Changes in corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) gene expression in the paraventricular nucleus of the hypothalamus and the anterior pituitary, respectively, and the ability of citalopram to inhibit serotonin reuptake were investigated. The exposure to three different stress models did not influence citalopram action on individual parameters of HPA axis and on serotonin reuptake. On the other hand, repeated administration of the drug led to significant attenuation of ACTH and CRH mRNA responses. The present results allow to suggest that the stressors used did not influence serotonergic neurotransmission to the extent that would modify HPA axis response to citalopram challenge. Activation of HPA axis by acute citalopram treatment was found to be accompanied by increased CRH gene expression in the hypothalamus. Repeated administration of the drug led to the development of tolerance to activation of central and peripheral components of HPA axis, but not to serotonin reuptake inhibition.
Moncek
Fedor
F
Institute of Experimental Endocrinology, Slovak Academy of Sciences, Vlarska 3, 83306 Bratislava, Slovakia.
Duncko
Roman
R
Jezova
Daniela
D
D000302:Adrenal Cortex / Q000187:drug effects* / Q000502:physiology; D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000235:genetics; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage; D015283:Citalopram / Q000008:administration & dosage*; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects; D007031:Hypothalamus / Q000187:drug effects* / Q000502:physiology; D008297:Male; D010286:Paraventricular Hypothalamic Nucleus / Q000737:chemistry; D010902:Pituitary Gland / Q000187:drug effects* / Q000502:physiology; D010903:Pituitary Gland, Anterior / Q000737:chemistry; D011333:Pro-Opiomelanocortin / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D012149:Restraint, Physical; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D013312:Stress, Physiological; D015430:Weight Gain / Q000187:drug effects
D000324:Adrenocorticotropic Hormone; D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D003345:Corticosterone; D003346:Corticotropin-Releasing Hormone; D011333:Pro-Opiomelanocortin; D012333:RNA, Messenger; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors